EPALINGES, Switzerland, Oct. 30, 2018 /PRNewswire/ -- Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases announces that new data will be presented at the 67th American Society of Tropical Medicine and Hygiene (ASTMH), held from October 28 – November 1, 2018 at in New Orleans, Louisiana.
Dr. David L. Narum of the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will discuss the results from an ongoing study in CD-1 mice investigating antibody titer strength, duration and functionality following Pfs230D1M antigen delivered in Mymetics' influenza virosome platform containing a membrane anchored TLR4 and/or TLR7/8 agonist. Included as a comparator is a point of injection formulation of Pfs230D1M-EPA with a TLR4 agonist and QS-21 in a liposomal formulation, similar to the clinical benchmark.
The poster with the title "Evaluation of the malaria transmission blocking vaccine antigen Pfs230D1M in an influenza virosome platform containing TLR agonists", will be presented on October 30th from noon to 1:45pm.
The poster highlights that virosomes containing the Pfs230D1M antigen and TLR7/8 agonist produced durable Pfs230D1M antibody titers over a period of 126 Days in CD-1 mice.
The titers and functional activity of sera generated by the Pfs230D1M OEG-TLR7/8 virosomes were not significantly different to those generated by an equivalent antigen dose in a liposomal formulation similar to the clinical benchmark.
The combination of TLR4 + TLR7/8 in the virosome did not increase titer or function of the TLR7/8 only virosome.
Transmission-blocking vaccine candidates seek to interrupt the life cycle of the parasite by inducing antibodies that prevent the parasite from maturing in the mosquito after it takes a blood meal from a vaccinated person. Since 2014, Mymetics and NIAID have been exploring alternative platforms for the development of a Transmission Blocking Vaccine (TBV). Virosomes offer the advantage to have both antigens and adjuvants on the same particle, there is no free-form adjuvant that could potentially lead to unspecific immune activation, reducing risk of side effects.
In previously announced study results with NIAID and PATH-MVI, studies showed that the virosome vaccine candidates, at the highest dose tested, generated high antibody titers against the required antigens and they were able to significantly reduce (97-100%) the transmission of the Plasmodium falciparum parasite.
According to the World Health Organization, in 2016, 91 countries had ongoing malaria transmission. There were an estimated 216 million cases of malaria in 2016 and an estimated 445 000 deaths.
Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, malaria, Chikungunya and the RSV vaccine and a collaborative project in the field of allergy Immunotherapy with Anergis SA.
Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. For further information, please visit www.mymetics.com.
Forward looking statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.
SOURCE Mymetics Corporation